SAGE insider transaction filings
Sage Therapeutics, Inc. — 28 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-07-31. Screen SAGE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-07-31 | 4 | Quirk Michael C. — See Remarks | Disposition to issuer (D): 24,999 · Disposition to issuer (D): 7,962 · Disposition to issuer (D): 36,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) | EDGAR |
| 2025-07-31 | 4 | Federer Jessica — Director | Disposition to issuer (D): 21,500 (derivative) | EDGAR |
| 2025-07-31 | 4 | Benecchi Christopher — Chief Operating Officer | Disposition to issuer (D): 28,053 · Disposition to issuer (D): 36,375 · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2025-07-31 | 4 | Barrett Elizabeth A. — Director | Code (U): 3,000 · Disposition to issuer (D): 21,500 (derivative) | EDGAR |
| 2025-07-31 | 4 | Shiferman Gregory L. — See Remarks | Code (U): 7,215 · Disposition to issuer (D): 23,735 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 28,000 (derivative) | EDGAR |
| 2025-07-31 | 4 | Golumbeski George — Director | Code (U): 8,000 · Disposition to issuer (D): 13,593 (derivative) · Disposition to issuer (D): 21,500 (derivative) | EDGAR |
| 2025-07-31 | 4 | Germano Geno J — Director | Disposition to issuer (D): 21,500 (derivative) | EDGAR |
| 2025-07-31 | 4 | Greene Barry E — President and CEO, Director | Code (U): 46,940 · Disposition to issuer (D): 53,229 · Disposition to issuer (D): 174,000 (derivative) | EDGAR |
| 2025-07-31 | 4 | FRATES JAMES M — Director | Code (U): 2,845 · Disposition to issuer (D): 19,154 (derivative) · Disposition to issuer (D): 21,500 (derivative) | EDGAR |
| 2025-07-31 | 4 | COLA MICHAEL F — Director | Disposition to issuer (D): 21,500 (derivative) | EDGAR |
| 2025-06-26 | 4 | Quirk Michael C. — See Remarks | Tax withholding (F): 113 @ $9.22 | EDGAR |
| 2025-06-26 | 4 | Shiferman Gregory L. — See Remarks | Tax withholding (F): 79 @ $9.22 | EDGAR |
| 2025-06-13 | 4 | Federer Jessica — Director | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Barrett Elizabeth A. — Director | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Golumbeski George — Director | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Germano Geno J — Director | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | FRATES JAMES M — Director | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | COLA MICHAEL F — Director | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Benecchi Christopher — Chief Operating Officer | Grant/award (A): 3,255 @ $0 · Tax withholding (F): 793 @ $6.91 · Grant/award (A): 2,712 @ $0 · Tax withholding (F): 661 @ $6.91 | EDGAR |
| 2025-04-11 | 4 | Quirk Michael C. — See Remarks | Grant/award (A): 933 @ $0 · Tax withholding (F): 312 @ $6.91 · Grant/award (A): 1,269 @ $0 · Tax withholding (F): 424 @ $6.91 | EDGAR |
| 2025-04-11 | 4 | Shiferman Gregory L. — See Remarks | Grant/award (A): 525 @ $0 · Tax withholding (F): 176 @ $6.91 | EDGAR |
| 2025-04-11 | 4 | Greene Barry E — President and CEO, Director | Grant/award (A): 19,964 @ $0 · Tax withholding (F): 4,862 @ $6.91 | EDGAR |
| 2025-04-02 | 4 | Quirk Michael C. — See Remarks | Grant/award (A): 2,000 @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Shiferman Gregory L. — See Remarks | Tax withholding (F): 79 @ $8.21 | EDGAR |
| 2025-02-25 | 4 | Shiferman Gregory L. — See Remarks | Tax withholding (F): 2,502 @ $7.49 | EDGAR |
| 2025-02-14 | 4 | Benecchi Christopher — Chief Operating Officer | Tax withholding (F): 822 @ $7.18 | EDGAR |
| 2025-02-14 | 4 | Gault Laura — Chief Medical Officer | Tax withholding (F): 685 @ $7.18 | EDGAR |
| 2025-02-14 | 4 | Shiferman Gregory L. — See Remarks | Tax withholding (F): 376 @ $7.18 · Tax withholding (F): 251 @ $7.18 | EDGAR |
Recent 8-K events — Sage Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-07-31 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2025-02-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SAGE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →